News

Shares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The clinical-stage bio

Shares of CymaBay Therapeutics (NASDAQ: CBAY) were sinking 11.3% lower this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. The decline

Stock valuations are at historically high levels. However, that doesn't mean you can't find stocks worth buying.

Three Motley Fool contributors identified bargain stocks to buy in a market that's

If you're an income investor, you may have heard tales of mighty companies that have raised their payouts no matter the economic cycle. Only 49 companies over the past 50 years have managed to

Dividends are great. They're a reliable source of passive income for retirees (and others) or can help boost long-term returns for investors who choose to reinvest them. But what happens when a

Fool.com contributor Parkev Tatevosian considers Invitae (NYSE: NVTA) stock and its financial prospects to determine if investors should buy the stock.

*Stock prices used were the afternoon prices

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

As the United

Regeneron Pharmaceuticals (NASDAQ: REGN) has made for a fantastic growth story over the years. From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion last

One of the key benefits of owning dividend stocks is the ability to reinvest the dividends to take advantage of the power of compounding. However, not all dividend stocks are table-pounding buys. A

The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech

CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12

Shares of American-New Zealand space company Rocket Lab USA (NASDAQ: RKLB) plunged 15.5% at the open on Tuesday after the company's 41st attempt at a rocket launch ended in failure this morning.

The

Pfizer (NYSE: PFE) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it. While its promise of steady returns and a decent dividend might be

Other than running out of money, what economic risk do Intellia Therapeutics, (NASDAQ: NTLA) CRISPR Therapeutics, (NASDAQ: CRSP) Bluebird Bio, (NASDAQ: BLUE) and a bunch of other cutting-edge

Gasoline prices are on the rise again. Inflation is too (thanks, in part, to rising gas prices). The Federal Reserve hasn't ruled out additional interest rate increases over the next several months

It's best not to go all in on high-risk stocks, but that doesn't mean you should avoid them entirely. If you can tolerate some risk, certain players could make a good addition to a diversified

AT&T (NYSE: T) claimed its divestments of DirecTV in 2021 and WarnerMedia in 2022 would herald a new beginning for its aging business. The sales did mark an end to the telecom giant's ill-advised

Shares of Scilex (NASDAQ: SCLX) were down more than 14% as of 1 p.m. ET on Monday, despite the company announcing positive phase 2 trial results for its non-opioid pain therapy SP-103. The healthcar

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

The US harvests

Fool.com contributor Parkev Tatevosian evaluates AT&T (NYSE: T) and answers if he thinks the stock is a buy.

*Stock prices used were the afternoon prices of Sept. 13, 2023. The video was published